MétaCan
Menu
Back to cohort
Record W4244239499 · doi:10.18632/oncotarget.15138

Introducing, OncoTarget

2010· article· en· W4244239499 on OpenAlexfundno aff
Mikhail V. Blagosklonny, Andrei V. Gudkov

Bibliographic record

VenueOncotarget · 2010
Typearticle
Languageen
FieldMedicine
TopicCancer-related Molecular Pathways
Canadian institutionsnot available
FundersMedical Research and Materiel CommandCancer Council TasmaniaNational Health and Medical Research CouncilMedical Research CouncilU.S. ArmyCancer Council VictoriaDeutsche KrebshilfeNational Cancer InstituteKuopion Yliopistollinen SairaalaKarolinska InstitutetAgency for Science, Technology and ResearchCanadian Institutes of Health ResearchCancer Institute NSWFonds Wetenschappelijk OnderzoekCancerfondenCancer AustraliaNational Breast Cancer FoundationBundesministerium für Bildung und ForschungNational Institute for Health and Care ResearchNational Institutes of HealthDavid F. and Margaret T. Grohne Family FoundationStockholms Läns LandstingCancer Council South AustraliaDeutsches KrebsforschungszentrumGénome QuébecMcGill UniversityU.S. Department of Health and Human ServicesNIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer ResearchItä-Suomen YliopistoUniversity of CambridgeBreast Cancer Research FoundationCancer Council NSWSusan G. Komen for the CureHelsingin ja Uudenmaan SairaanhoitopiiriKWF KankerbestrijdingCancer Research UK
KeywordsMedicine

Abstract

fetched live from OpenAlex

TP53 overexpression is indicative of somatic TP53 mutations and associates with aggressive tumors and poor prognosis in breast cancer.We utilized a twostage SNP association study to detect variants associated with breast cancer survival in a TP53-dependent manner.Initially, a genome-wide study (n = 575 cases) was conducted to discover candidate SNPs for genotyping and validation in the Breast Cancer Association Consortium (BCAC).The SNPs were then tested for interaction with tumor TP53 status (n = 4,610) and anthracycline treatment (n = 17,828).For SNPs interacting with anthracycline treatment, siRNA knockdown experiments were carried out to validate candidate genes.In the test for interaction between SNP genotype and TP53 status, we identified one locus, represented by rs10916264 (p (interaction) = 3.44 × 10 -5 ; FDR-adjusted p = 0.0011) in estrogen receptor (ER) positive cases.The rs10916264 AA genotype associated with worse survival among cases with ER-positive, TP53-positive tumors (hazard ratio [HR] 2.36, 95% confidence interval [C.I] 1.45 -3.82).This is a cis-eQTL locus for FBXO28 and TP53BP2; expression levels of these genes were associated with patient survival specifically in ER-positive, TP53-mutated tumors.Additionally, the SNP rs798755 was associated with survival in interaction with anthracycline treatment (p (interaction) = 9.57 × 10 -5 , FDR-adjusted p = 0.0130).RNAi-based depletion of a predicted regulatory target gene, FAM53A, indicated that this gene can modulate doxorubicin sensitivity in breast cancer cell lines.If confirmed in independent data sets, these results may be of clinical relevance in the development of prognostic and predictive marker panels for breast cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: none
Teacher disagreement score0.472
Threshold uncertainty score0.673

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0020.002
Science and technology studies0.0010.001
Scholarly communication0.0050.001
Open science0.0020.003
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.5280.401

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.255
Teacher spread0.249 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2010
Admission routes1
Has abstractyes

Explore more

Same venueOncotargetSame topicCancer-related Molecular PathwaysFrench-language works237,207